Core Insights - Legend Biotech is presenting six poster presentations on CARVYKTI at the upcoming Tandem Meetings, showcasing its efficacy, safety, and real-world outcomes in treating multiple myeloma [1][4]. Group 1: CARVYKTI Efficacy and Safety - CARVYKTI has treated over 10,000 patients globally, generating substantial clinical and real-world evidence for its use in multiple myeloma treatment [2]. - The therapy demonstrates consistent and durable efficacy and safety, particularly when administered earlier in the treatment journey, leading to meaningful quality-adjusted survival gains [3][4]. - CARVYKTI is the first and only BCMA-targeted CAR-T cell therapy approved for patients with multiple myeloma who have undergone at least one prior line of therapy, and it is now available in 14 countries [4]. Group 2: Poster Presentations Overview - The six poster presentations will cover various aspects of CARVYKTI, including quality-adjusted survival analysis, management of neurologic events, and the impact of bridging therapy on treatment outcomes [5][6]. - Specific topics include the characterization of neurologic events, the relationship between bridging therapy response and safety outcomes, and long-term progression-free survival benefits [5][6]. Group 3: Industry Context - Multiple myeloma is an incurable blood cancer with an estimated 35,000 new diagnoses and over 12,000 deaths in the U.S. in 2024, highlighting the critical need for effective treatments like CARVYKTI [58]. - Legend Biotech is positioned as a leader in cell therapy, focusing on maximizing patient access and therapeutic potential of CARVYKTI while expanding its pipeline of innovative treatments [59].

Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇宣佈截至2025年12月31日止季度 CARVYKTI®的初步銷售額 本自願性公告由金斯瑞生物科技股份有限公司（「本公司」）作出。 茲提述本公司日期爲2025年4月15日、2025年7月16日及2025年10月14日的公告，内容 分別有關截至2025年3月31日止季度、截至2025年6月30日止季度及截至2025年9月30日 止季度CARVYKTI®的初步銷售額。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 1 或有效性資料或資料分析，或一般的政府監管；因傳奇的第三方合作夥伴採取的行動 或未有採取行動而導致的意外延誤；因對傳奇的專利或其他專有知識產權保護提出質 疑而產生的不確定性，包括美國訴訟程序中涉及的不確定性；一般競爭；政府、行業 和公眾定價和其他政治壓力；以及於2025年3月11日向美國證券交易委員會提交的傳奇 ...

Core Insights - Legend Biotech will present significant data on CARVYKTI for multiple myeloma at the upcoming ASH Annual Meeting, showcasing the therapy's effectiveness and safety profile [1][3][5] - The company is also introducing first-in-human data for Lucar-G39D, a novel allogeneic CAR-T therapy for B-cell non-Hodgkin lymphoma [2][3] CARVYKTI Presentations - Two oral presentations and seven poster presentations will focus on CARVYKTI, emphasizing its long-term progression-free survival and immune fitness benefits [1][4] - CARVYKTI is the first BCMA-targeted CAR-T cell therapy approved for multiple myeloma, currently available in 14 countries and used to treat over 9,000 patients globally [3][4] Lucar-G39D Development - An oral presentation will detail the investigational Lucar-G39D therapy, which targets both CD20 and CD19 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma [2][7] - This therapy represents Legend Biotech's efforts to expand its pipeline into next-generation allogeneic cell therapies [3] Clinical Trials and Studies - The CARTITUDE-4 study is an ongoing Phase 3 trial comparing cilta-cel with standard therapies for relapsed and lenalidomide-refractory multiple myeloma [58] - The CARTITUDE-1 study evaluates cilta-cel's safety and efficacy in patients with advanced multiple myeloma who have undergone multiple prior therapies [59] Company Overview - Legend Biotech is a leader in cell therapy, focusing on innovative treatments for cancer, particularly through CAR-T therapies like CARVYKTI [63] - The company collaborates with Janssen Biotech for the development and commercialization of cilta-cel, which has received multiple regulatory designations and approvals [56][57]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇宣佈截至2025年9月30日止季度 CARVYKTI®的初步銷售額 本公告以英文發佈，並附有中文翻譯。如中英文版本有任何不一致或歧義，應以英文 版為准。 本公司股東及潛在投資者務請注意投資風險，並於買賣或擬買賣本公司證券時審慎行 事。 承董事會命 Genscript Biotech Corporation 孟建革 主席及執行董事 關於前瞻性陳述的警示性說明 本公告中關於未來預期、計劃和前景的陳述，以及關於非歷史事實事項的任何其他陳 述，均構成《1995年私人證券訴訟改革法案》所界定的「前瞻性陳述」。這些陳述包 括但不限於與CARVYKTI®有關的陳述，包括傳奇對CARVYKTI®貿易銷售淨額和由此 產生的毛利的預期。「預期」、「相信」、「繼續」、「可能」、「估計」、「期 望 ...